Pacira BioSciences (NASDAQ:PCRX) Price Target Raised to $30.00

Pacira BioSciences (NASDAQ:PCRX - Get Free Report) had its target price hoisted by investment analysts at Needham & Company LLC from $22.00 to $30.00 in a research note issued on Monday,Benzinga reports. The brokerage presently has a "buy" rating on the stock. Needham & Company LLC's target price indicates a potential upside of 40.12% from the stock's current price.

A number of other research analysts have also recently commented on the stock. HC Wainwright reaffirmed a "buy" rating and issued a $39.00 target price on shares of Pacira BioSciences in a research report on Wednesday, December 4th. Royal Bank of Canada increased their price objective on shares of Pacira BioSciences from $15.00 to $16.00 and gave the stock a "sector perform" rating in a research report on Thursday, November 7th. Barclays cut their target price on Pacira BioSciences from $25.00 to $17.00 and set an "equal weight" rating on the stock in a research report on Tuesday, November 12th. Finally, Jefferies Financial Group upped their price target on Pacira BioSciences from $15.00 to $18.00 and gave the stock a "buy" rating in a research note on Tuesday, September 24th. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $24.30.

Pacira BioSciences Trading Up 3.7 %

Shares of Pacira BioSciences stock traded up $0.77 during trading hours on Monday, hitting $21.41. The company's stock had a trading volume of 247,943 shares, compared to its average volume of 645,371. The stock has a market cap of $988.56 million, a price-to-earnings ratio of -10.55 and a beta of 0.76. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.89 and a current ratio of 2.25. Pacira BioSciences has a twelve month low of $11.16 and a twelve month high of $34.01. The firm has a fifty day moving average of $18.27 and a 200-day moving average of $17.59.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. The Manufacturers Life Insurance Company boosted its stake in shares of Pacira BioSciences by 6.0% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 23,932 shares of the company's stock valued at $685,000 after buying an additional 1,354 shares during the period. Profund Advisors LLC lifted its stake in Pacira BioSciences by 26.2% in the second quarter. Profund Advisors LLC now owns 10,551 shares of the company's stock worth $302,000 after acquiring an additional 2,190 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its stake in Pacira BioSciences by 62.3% in the third quarter. China Universal Asset Management Co. Ltd. now owns 8,872 shares of the company's stock worth $134,000 after acquiring an additional 3,404 shares during the last quarter. Mercer Global Advisors Inc. ADV grew its holdings in Pacira BioSciences by 39.0% during the 2nd quarter. Mercer Global Advisors Inc. ADV now owns 12,686 shares of the company's stock worth $363,000 after acquiring an additional 3,562 shares in the last quarter. Finally, Quest Partners LLC purchased a new stake in shares of Pacira BioSciences in the 2nd quarter valued at approximately $113,000. 99.73% of the stock is owned by institutional investors and hedge funds.

About Pacira BioSciences

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.